ARRAY BIOPHARMA INC's ticker is and the CUSIP is 04269XAA3. A total of 22 filers reported holding ARRAY BIOPHARMA INC in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $5,655,000 | +4.4% | 4,748,000 | -26.3% | 0.08% | -2.4% |
| Q2 2016 | $5,418,000 | -19.5% | 6,442,000 | -23.7% | 0.08% | -18.4% |
| Q1 2016 | $6,727,000 | -20.7% | 8,442,000 | -6.1% | 0.10% | -21.4% |
| Q4 2015 | $8,481,000 | -17.6% | 8,993,000 | -14.3% | 0.13% | -16.6% |
| Q3 2015 | $10,288,000 | -22.8% | 10,493,000 | -0.0% | 0.16% | -18.2% |
| Q2 2015 | $13,326,000 | +1.1% | 10,495,000 | -0.0% | 0.19% | +0.5% |
| Q1 2015 | $13,187,000 | +32.3% | 10,499,000 | -1.4% | 0.19% | +30.8% |
| Q4 2014 | $9,964,000 | -33.1% | 10,646,000 | -37.1% | 0.15% | -36.5% |
| Q3 2014 | $14,893,000 | -10.4% | 16,919,000 | -7.9% | 0.23% | -7.3% |
| Q2 2014 | $16,618,000 | -18.2% | 18,374,000 | -6.6% | 0.25% | -21.8% |
| Q1 2014 | $20,318,000 | -2.4% | 19,669,000 | -1.3% | 0.32% | +21.0% |
| Q4 2013 | $20,824,000 | +27.7% | 19,919,000 | +41.3% | 0.26% | +19.6% |
| Q3 2013 | $16,313,000 | – | 14,100,000 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 45,000,000 | $62,545,000 | 2.57% |
| Redmile Group, LLC | 9,000,000 | $12,593,000 | 1.09% |
| CSS LLC/IL | 8,744,000 | $12,199,000 | 0.67% |
| LINDEN ADVISORS LP | 11,000,000 | $15,400,000 | 0.60% |
| Telemetry Investments, L.L.C. | 750,000 | $1,049,000 | 0.59% |
| WOLVERINE ASSET MANAGEMENT LLC | 15,250,000 | $21,453,000 | 0.28% |
| OAKTREE CAPITAL MANAGEMENT LP | 12,500,000 | $17,419,000 | 0.26% |
| Fernwood Investment Management, LLC | 90,000 | $126,000 | 0.12% |
| Baker Brothers Advisors | 3,000,000 | $4,195,000 | 0.04% |
| Citadel Advisors | 18,306,000 | $25,712,000 | 0.03% |